8-K: Conduit Pharmaceuticals Granted Nasdaq Extension, Regains Bid Price Compliance

Conduit Pharmaceuticals receives an extension from Nasdaq to regain compliance with MVPHS and MVLS rules, while also achieving compliance with the Minimum Bid Price rule.

Summary

• Conduit Pharmaceuticals Inc. received an extension from The Nasdaq Stock Market LLC to regain compliance with certain listing rules.
• The extension pertains to the Market Value of Publicly Held Shares (MVPHS) and Market Value of Listed Securities (MVLS) rules.
• To maintain compliance, Conduit Pharmaceuticals must file an application to transfer to the Nasdaq Capital Market by March 12, 2025.
• The company must also demonstrate compliance with all Nasdaq listing rules by March 31, 2025.
• As of February 26, 2025, Conduit Pharmaceuticals regained compliance with the Minimum Bid Price rule.
• Following the transfer, the company's MVPHS is expected to meet the continued listing standard of greater than $1.0 million.
• Conduit Pharmaceuticals believes it will demonstrate compliance with the Equity Standard of Stockholders Equity greater than $2.5 million before the March 31, 2025, deadline.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company received an extension, which is good, but still needs to meet requirements to maintain its listing. There is also a risk that they will not be able to meet the requirements.

Positives

• Nasdaq granted Conduit Pharmaceuticals an extension to regain compliance with MVPHS and MVLS rules.
• Conduit Pharmaceuticals regained compliance with the Minimum Bid Price rule as of February 26, 2025.
• The company believes it will be able to demonstrate compliance with the Equity Standard of Stockholders Equity greater than $2.5 million before the March 31, 2025, deadline.

Risks

• There is no assurance that Conduit Pharmaceuticals will be able to demonstrate compliance with the Equity Standard of Stockholders Equity greater than $2.5 million before the March 31, 2025, deadline.
• Failure to meet the conditions set by Nasdaq could result in delisting.

Future Outlook

Conduit Pharmaceuticals intends to file an application to transfer to the Nasdaq Capital Market by March 12, 2025, and believes it will satisfy all Nasdaq listing rules by March 31, 2025.

Management Comments

• Conduit Pharmaceuticals believes it will be able to demonstrate its compliance with the Equity Standard of Stockholders Equity greater than $2.5 million prior to the March 31, 2025, deadline to the satisfaction of Nasdaq.

Industry Context

Many small cap pharmaceutical companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the need to raise capital.

Comparison to Industry Standards

• Maintaining compliance with Nasdaq listing requirements is a common challenge for companies in the biotechnology and pharmaceutical sectors, especially those with smaller market capitalizations.
• Companies like XOMA Corporation and Ocugen Inc. have faced similar compliance issues related to minimum bid price and market capitalization in the past.
• These companies often implement strategies such as reverse stock splits or capital raising to regain compliance, similar to Conduit Pharmaceuticals' plan to transfer to the Nasdaq Capital Market and demonstrate compliance with the Equity Standard.

Stakeholder Impact

• Shareholders are impacted by the company's ability to maintain its Nasdaq listing.
• Employees are indirectly impacted as the company's financial stability is tied to its listing status.

Next Steps

• File an application to transfer to the Nasdaq Capital Market by March 12, 2025.
• Demonstrate compliance with all Nasdaq listing rules by March 31, 2025.

Key Dates